A trial of dasatinib for children and young people with Philadelphia positive leukaemia (CA180-226)

This trial looked at how well a type of targeted drug called dasatinib worked for children and young people with Philadelphia chromosome positive leukaemia.

The trial was for children and young people up to and including the age of 18. We use the term ‘you’ in this summary, but if you are a parent, we are referring to your child.

These results were published in 2018.